SEP 16, 2020 2:54 PM PDT

Does Discontinuation of Immunotherapy Effect Final Results in Metastatic Melanoma?

WRITTEN BY: Jasper Cantrell

The last decade has seen the emergence of several new therapies against cancer. For melanoma, checkpoint inhibitors have become the go-to treatments or “first-line therapies.”

The inhibitors in question are pembrolizumab, nivolumab, and the combination therapy ipilimumab/nivolumab. All three have comparable results and are considered the standard treatments for melanoma. Unfortunately, instances of melanoma are on the rise, and survival rates for metastatic melanoma are a quarter of what they are for local melanomas.

A new study from McGill University in Canada wanted to examine how discontinuation of first-line therapy for metastatic melanoma patients affected the final results. The team hypothesized that clinical trials don’t represent real-world patients due to patient criteria often found in trials. This new study would remedy that by using real-world patient data to reveal useful information on how discontinuation of treatment affected results.

They utilized several databases to gather data from 876 patients with metastatic melanoma. They found that pembrolizumab was the most common treatment, followed by nivolumab and the ipilimumab/nivolumab combination therapy. All three have relatively similar effectiveness, but pembrolizumab may offer slightly better results, making it more popular for doctors and patients.

The team also noted that pembrolizumab had the longest therapy time, with an average of 12 months before the treatment was halted. Combination therapy had the earliest discontinuation time, which contrasted with the generally better responses it gets. Combination therapy was also more likely to end with no progression onto a second-line therapy than the monotherapies, which tended to move onto second-line therapy. Disease progression and immune-related issues were the most common reasons for discontinuation.

This study identified pembrolizumab as the most common and most stable as far as therapy length goes. A determination of sufficient therapy length couldn’t be determined with the data on hand, but several important factors concerning treatment were identified.

The study concludes, “In conclusion, these real-world data demonstrated that a large proportion of patients discontinued initial therapy with pembrolizumab, nivolumab, or nivolumab/ipilimumab before two years and that difference in therapy discontinuation was very small or not detectable between patients initiating those therapies, but with trends for lower discontinuation with pembrolizumab.”

Sources: Nature Scientific Reports, Mayo Clinic

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUL 11, 2020
Cancer
New drug combo could improve immunotherapy for SCCOHT ovarian cancer
JUL 11, 2020
New drug combo could improve immunotherapy for SCCOHT ovarian cancer
Research published recently in PLOS ONE reports on SP-2577, a drug that could help girls and young women plagued with a ...
JUL 23, 2020
Immunology
Cancer Therapy Reduces Lung Scarring
JUL 23, 2020
Cancer Therapy Reduces Lung Scarring
Scientists at the Stanford Institute for Stem Cell Biology and Regenerative Medicine have discovered a striking parallel ...
AUG 09, 2020
Cancer
Reducing post-surgery metastasis in colorectal cancer patients
AUG 09, 2020
Reducing post-surgery metastasis in colorectal cancer patients
Scientists have recently shown the successful reduction of metastasis in post-surgery colorectal cancer patients. The st ...
AUG 24, 2020
Cancer
Inhibiting Cancer Stem Cells to Stop Cancer Recurrence
AUG 24, 2020
Inhibiting Cancer Stem Cells to Stop Cancer Recurrence
Once upon a time, stem cells were the talk of the town. They really are amazing, with some capable of turning into any o ...
SEP 09, 2020
Cancer
Microbubbles enhance delivery of chemotherapy drug
SEP 09, 2020
Microbubbles enhance delivery of chemotherapy drug
New research published in APL Bioengineering reports on a new technology developed by scientists at Tulane Universi ...
SEP 18, 2020
Coronavirus
How Coronavirus Spread in the US and Europe
SEP 18, 2020
How Coronavirus Spread in the US and Europe
Researchers are beginning to examine how the world's response to the pandemic virus SARS-CoV-2 went wrong, and right ...
Loading Comments...